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It has recently been suggested that the Lublin-Reingold clinical classification of multiple sclerosis (MS) 
be modified to include the use of magnetic resonance imaging (MRI). An international consensus 
conference sponsored by the Consortium of Multiple Sclerosis Centers (CMSC) was held from March 5 
to 7, 2010, to review the available evidence on the need for such modification of the Lublin-Reingold 
criteria and whether the addition of MRI or other biomarkers might lead to a better understanding 
of MS pathophysiology and disease course over time. The conference participants concluded that 
evidence of new MRI gadolinium-enhancing (Gd+) T1-weighted lesions and unequivocally new 
or enlarging T2-weighted lesions (subclinical activity, subclinical relapses) should be added to the 
clinical classification of MS in distinguishing relapsing inflammatory from progressive forms of 
the disease. The consensus was that these changes to the classification system would provide more 
rigorous definitions and categorization of MS course, leading to better insights as to the evolution and 
treatment of MS. Int J MS Care. 2012;14:105–114.
It was recently suggested by Lincoln et al.
1 that 
the Lublin-Reingold clinical classification of 
multiple sclerosis (MS)2 for the assessment of MS 
phenotypes and patient evolution over time be modified 
to include magnetic resonance imaging (MRI). It was 
recommended that the classification incorporate the 
“conventional,” generally available MRI techniques of 
gadolinium (Gd) T1-weighted sequences and dual-echo 
and fluid-attenuated inversion recovery (T2-weighted 
and FLAIR) images (Table 1). It was recognized that 
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course over time and, in turn, more informed clinical 
trials and a better understanding of appropriate 
therapies.
Prior to the meeting, a survey of members of the 
CMSC was conducted on the need to modify the 
Lublin-Reingold classification. Over a 1-week period, 
141 responses were received, representing 16% of the 
CMSC members polled. The results were as follows: A 
total of 70% of respondents indicated that the Lublin-
Reingold classification did not sufficiently distinguish 
the different forms of MS; 87% felt that the Lublin-
Reingold classification did not sufficiently distinguish 
MS disease activity even within a given category of the 
disease; and 84% indicated that it would be useful to 
include certain subclinical indices of disease activity 
in the clinical classification, such as MRI gadolinium-
other MRI modalities that are not currently widely 
available and other validated biomarkers might be added 
to the classification in the future. 
In response to the publication of Lincoln et al.,1 the 
Consortium of Multiple Sclerosis Centers (CMSC) 
sponsored an international consensus conference, which 
was held in Short Hills, New Jersey, from March 5 
to 7, 2010. Participating in the conference were 28 
invited MS experts from North and South America 
and Europe who were well versed in clinical trials, the 
management of MS, biostatistics, neuropathology, 
neuroimaging, and neuroimmunology. The goal of the 
meeting was to review the available evidence on the 
need for modification of the Lublin-Reingold criteria 
and whether addition of MRI and other biomarkers 
as proposed by Lincoln et al.1 would lead to a better 
understanding of MS pathophysiology and disease 
Table 1. Definitions of relapse by both clinical and MRI measuresa
MS groups Revised classification Lublin-Reingold classification2
Relapsing forms
   Clinical RR Clinical relapse with near complete or complete 
recovery to baseline neurological examination 
findings
RR MS: “Clearly defined disease relapses 
[clinical relapse] with full recovery or 
with sequelae and residual deficit upon 
recovery; periods between disease 
relapses characterized by a lack of disease 
progression”
   Clinical relapsing-nonremitting Clinical relapse with minimal if any recovery to 
baseline neurological examination findings
   Subclinical relapse As defined below
Progressive forms
   Secondary progressive Initial relapsing disease with subsequent 
progression as defined below; patients may then 
have continued progression, stability, or recurrent 
relapse
“Initial RR disease course followed by 
progression with or without occasional 
relapses [clinical relapse], minor remissions, 
and plateaus”
   Progressive relapsing Progression, as defined below, from onset of 
disease with superimposed clinical or subclinical 
relapses
“Progressive disease from onset, with clear 
acute relapses, with or without full recovery; 
periods between relapses characterized by 
continuing progression”
   Primary progressive Progression, as defined below, from onset 
of disease in the absence of either clinical or 
subclinical relapses
“Disease progression from onset with 
occasional plateaus and temporary minor 
improvements allowed”
Source: Reprinted with permission from Lincoln et al.1 Copyright ©2009 American Medical Association. All rights reserved.
Abbreviations: MRI, magnetic resonance imaging; MS, multiple sclerosis; RR, relapsing-remitting.
aMagnetic resonance imaging evaluation along with a neurological examination should be performed at regular intervals. “Relapses” include 
(1) Clinical relapse: New or worsening neurological symptoms of central nervous system dysfunction plus 2-grade increase in 1 or more 
Kurtzke functional scale scores or 1-grade increase in 2 or more functional scale scores in the absence of fever, lasting greater than 24 hours, 
and preceded by at least 30 days of clinical stability. (2) Subclinical (MRI) relapse: Evidence of gadolinium enhancement on routine follow-up 
MRI of the brain and/or spinal cord in the absence of new symptoms indicates “current subclinical relapse,” while evidence of unequivo-
cally new or enlarging T2 lesions should indicate “remote subclinical relapse” occurring at some time since the last MRI. “Progression” is the 
objective evidence of increased deterioration in neurological examination findings on 2 visits at least 6 months apart in the absence of either 
clinical or subclinical relapse.
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Historical Analysis and Critique of the Lublin-
Reingold Criteria
The Lublin-Reingold MS classification has made 
important contributions to the definition of various 
MS phenotypes and classical stages on purely clinical 
grounds. The classification consists of four categories of 
MS: 1) relapsing-remitting MS (RRMS), characterized 
by clearly defined episodes of acute neurologic 
worsening with a variable degree of recovery and a stable 
course between attacks; 2) secondary progressive MS 
(SPMS), in which one or more relapses are followed 
by mainly progressive deterioration, possibly with some 
plateaus, new relapses, and even slight or transient 
improvement over time; 3) primary progressive MS 
(PPMS), consisting of continuous, often slow progres-
sion from the onset of symptoms, possibly with some 
plateauing without obvious relapses; and 4) progressive 
relapsing MS (PRMS), in which progression occurs 
from the onset of neurologic symptoms, with occasional 
relapses thereafter. Whether the latter is really a distinct 
category or represents a variant of relapsing or another 
progressive form of MS is unclear. Moreover, it may be 
the case that each of these categories is actually hetero-
geneous, with mild clinical or subclinical relapses not 
being adequately recognized.1,12-14 Despite these limita-
tions, the Lublin-Reingold classification has facilitated 
patient selection for enrollment in clinical trials and 
determination of which patients may be most likely to 
respond to approved drugs. 
A potential shortcoming of the Lublin-Reingold 
classification is that it is often difficult to determine the 
transition from a relapsing to a progressive form of the 
disease on purely clinical grounds.15 Using MRI metrics 
to assess subclinical disease activity, in addition to diag-
nosing disease, might identify patients with subclinical 
relapses rather than true progression. A purely clinical 
classification depends heavily on the patient history, 
which may not always be a sensitive or accurate mea-
sure, particularly over long periods of time. Progression 
of MS may also be difficult to assess by treating physi-
cians because of inter- and intra-examiner variability, 
limitations in the accuracy and comprehensiveness of the 
Expanded Disability Status Scale (EDSS) as a measure-
ment tool, the slow rate of deterioration in some 2-year 
clinical trials, and other possible factors such as medica-
tion side effects, lack of sleep, depression, and time of 
day.16-18 Furthermore, even sustained EDSS progression 
in research studies may reverse after study completion.19  
enhancing (Gd+) T1-weighted lesions or unequivocally 
new or enlarging T2-weighted lesions. Although 
this poll reflected the opinions of a relatively small 
proportion of the CMSC membership over a short 
period of time, the results supported the concept that 
changes to the Lublin-Reingold classification should be 
considered.
Presentations at the meeting included an overview of 
MRI in various categories of MS, from clinically isolated 
syndrome (CIS) to primary progressive MS (PPMS) 
(Li, Arnold); the pathology of MS and of MRI lesions 
from CIS to PPMS (Moore, Lucchinetti); a historical 
review of diagnostic and clinical classifications of MS 
as well as neuromyelitis optica (NMO), radiologically 
isolated syndrome (RIS), and CIS (Lublin, Kinkel); 
possible explanations for the so-called MRI-clinical 
paradox (Miller, Simon); recent evidence supporting 
a relationship between MRI and clinical endpoints 
(Sormani, Cutter); the concept of the disease-free state 
(Giovannoni, Naismith); the status of biomarkers 
for MS clinical activity (Dhib-Jalbut, Cadavid); 
and a proposal for modifying the Lublin-Reingold 
classification (Cook, Lisak). These presentations and 
reviews with updates are summarized below. 
Background
Historical Evolution of MS Diagnostic Criteria
Criteria for establishing the diagnosis of MS have 
evolved considerably over almost 50 years. The 
Schumacher Committee recommendations issued in 
1965 were purely clinical,3 while the Poser Committee 
revision of 1983 incorporated laboratory as well as 
clinical criteria.4 Most recently, the various iterations 
of the McDonald Committee criteria (2001, 2005, 
2010) used MRI (Gd+ lesions, new T2 lesions) and 
other laboratory findings in addition to purely clinical 
criteria for disease diagnosis.5-7 The occurrence of at 
least two relapses and dissemination of lesions in space 
are fundamental to the diagnosis of relapsing-remitting 
MS (RRMS); however, conventional MRI (Gd+ 
lesions, new T2 lesions) has become a surrogate for the 
second relapse and dissemination of disease in space and 
time. New MRI lesions have expedited the diagnostic 
evolution of CIS to definite RRMS,5-7 resulting in earlier 
diagnosis and treatment of MS.8,9 Whether MRI can be 
used as a marker for the first subclinical attack of MS in 
RIS, as for the second attack in diagnosing MS, is under 
consideration.10,11 
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all new T2 lesions (95–100%) as well as acute, transient, 
and chronic black holes (those lasting for more than 12 
months) occur coincidentally with or evolve from Gd+ 
T1-weighted lesions.37,49 However, Gd+ lesions evolve 
into chronic black holes less commonly than they do 
into T2 lesions or transient black holes.37 This indicates 
that unequivocally (not related to technique, position-
ing, quality of scan, or questionable reader interpetation) 
new T2 lesions or black holes in RRMS patients had a 
prior inflammatory phase with alteration of the BBB of 
a degree sufficient to be detected, even though this may 
not always be documentable with less frequent or sensi-
tive MRI.37   
It has been shown that T2 lesions have heterogeneous 
pathology, with varying degrees of abnormality rang-
ing from edema and inflammation with phagocytosis 
of myelin, to demyelination, gliosis, and axonal loss, 
which can be mild to severe.41-48 However, it is generally 
recognized that the underlying pathology responsible 
for enhancement is inflammation with accompanying 
BBB breakdown. In contrast to T2 lesions, it has 
been reported that T1 hypointensities or black holes, 
particularly chronic black holes, correlate better with 
physical disability, tissue injury including severe demy-
elination and axonal injury, and brain atrophy.42,45,50-52 
Recent evidence suggests that the size and duration of 
enhancing lesions, increased radial diffusion on dif-
fusion tensor imaging (DTI), and lower magnetic 
transfer ratio (MTR) predispose to chronic black holes, 
matrix destruction, and brain atrophy.34,45,46,53-60 Some 
controversy remains as to the degree of inflammation 
found in MS cortical lesions as compared with white 
matter lesions on histologic examination, but these 
differences are probably related to stage of MS (early vs. 
chronic disease).61-63    
Newer MRI techniques, currently experimental in 
nature, are giving us a glimpse of what these modalities 
may tell us in the future about MRI brain pathology 
and clinical relevance. These include magnetic transfer 
imaging (MTI), DTI, proton MRI spectroscopy, func-
tional MRI (fMRI), double inversion recovery (DIR) 
MRI, subtraction techniques, and ultra-high-field MRI 
scanners.64-66 For example, the degree of increase in 
fMRI activity has been reported to be proportional to 
the sensitivity of T2 lesion load up to a critical limit, at 
which time these important compensatory mechanisms 
(ie, plasticity) fail.34 Gray matter lesion conspicuity is 
increased with DIR techniques as well as with ultra-
Moreover, it is likely that an inflammatory compo-
nent of disease is present either always or at some time in 
all stages of MS.20-24 Indeed, Gd+ lesions, which indicate 
both an abnormality in blood-brain barrier (BBB) and 
central nervous system (CNS) inflammation, can occur 
not only in RRMS but in all Lublin-Reingold forms 
of MS, including in 14.1% to 42% of patients with 
PPMS.12-14 Pathologically inflammatory CNS lesions 
have also been described in all forms of MS, with or 
without the presence of Gd+ lesions, although the dis-
tribution of inflammatory lesions can vary in location or 
intensity in different forms of the disease.20-24  
When sensitive and frequent MRI studies are per-
formed, Gd+ and unequivocally new or enlarging T2 
brain lesions (subclinical relapses) can occur much more 
commonly than clinical symptoms (relapses or pro-
gression).25-28 This may be explained at least in part by 
several factors: lesions in “eloquent” brain areas such as 
the optic nerves are more likely to be clinically expressed 
than lesions in less eloquent pathways; the degree of 
matrix and axonal destruction may vary; and the poten-
tial exists for rapid symptom recovery.29-38 Even patients 
with progressive forms of MS, particularly those with 
Gd+ lesions indicating a subclinical relapse, may respond 
clinically to disease-modifying therapies (DMTs). For 
example, in a post hoc analysis of the Olympus trial 
of rituximab in PPMS, patients with Gd+ lesions had 
a significantly better response to treatment than those 
without Gd+ lesions.13
In summary, magnetic resonance imaging is the 
“gold standard” for evaluating drugs in phase 2 trials 
and is often used by clinicians, along with assessment 
of the presence of clinical relapses and progression, in 
making therapeutic decisions. Indeed, “freedom from 
disease activity” assessed both clinically and using MRI is 
increasingly regarded as an optimal outcome by which to 
judge the effectiveness of therapy.39,40 
Relationship of MRI to CNS Pathology
A limited number of biopsy and necropsy stud-
ies have been carried out involving Gd+ T1-weighted 
lesions, T2-weighted lesions, and T1 hypointense 
lesions or “black holes” in an attempt to correlate CNS 
pathology with identified MRI abnormalities.41-48 In 
considering the histologic characteristics of classic MS 
MRI lesions, it is important to recognize that when 
frequent, sensitive longitudinal (weekly or monthly)37,49 
MRI studies are performed in RRMS patients, almost 
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both relapsing and progressive forms of MS18,19,31; the 
EDSS is a relatively insensitive barometer of progres-
sion; and pseudoprogression may occur, making it dif-
ficult to accurately assess stability, worsening, or even 
mild improvement over the short term.16,17,19 Progres-
sion of cognitive dysfunction is more problematic to 
clearly document, by either routine clinical or routine 
imaging metrics. Mild-to-moderate cognitive impair-
ment may not be readily detected even by competent 
physicians or on EDSS testing, which is insensitive to 
such changes,16-18 nor can cortical gray matter lesions be 
easily detected with conventional MRI techniques.67,68 
However, cortical lesions are much more commonly 
detected pathologically and on MRI with DIR and 
high-field scans and documented much more easily with 
neuropsychological testing, even early in the patient’s 
course.18,74,84-86 
Furthermore, in both clinical practice and study 
trials, neither frequent brain MRI scans nor even infre-
quent spinal cord MRI scans are regularly obtained, 
so that many overt MRI lesions in the neuraxis can be 
missed, and previously hypointense or hyperintense 
lesions can become isointense and be difficult to detect 
unless prior MRI studies have been done.18,87,88 In such 
instances, structural damage may still be identified with 
DTI or MTI in former T2 lesions or black holes that 
have subsequently become isointense.87,88 
Lastly, although most if not all focal Gd+, T2, and 
T1 hypointense lesions may cause damage to the brain 
parenchyma, there may be sufficient reserves in neural 
pathways—with redundancies in critical thresholds of 
axonal function, or even compensatory mechanisms 
including plasticity and regeneration (particularly early 
in the course of MS)—so that new neurologic deficits or 
progression in disability may not be readily seen.19,31,89 
Ultimately, however, sufficient axonal loss may accu-
mulate over time (albeit at a unique rate in each patient) 
so that deterioration occurs, even when overt new MRI 
lesions are not identified.89  
All of the above could decrease MRI lesion conspicu-
ity on conventional scanning and affect the correlation 
of MRI lesions with clinical phenotypes, relapses, and 
progression. 
Evidence That the MS MRI-Clinical 
Paradox Is Disappearing
Individual MRI-Clinical Studies
The relevance of MRI-clinical relationships has 
changed remarkably in recent years.31 A large and grow-
high-field MRI scanners.67,68 The latter may even allow 
one to identify remyelination and distinguish perivenous 
lesions caused by demyelinating diseases from those 
caused by other neurologic disorders.69,70 There is also 
recent evidence that focal MRI white matter lesions in 
the optic radiations may lead to retrograde gray matter 
atrophy in the lateral geniculate nucleus.71 Even in 
normal-appearing white matter, abnormalities have 
been detected with DTI, MTI, and pathologic analysis 
that may be associated with clinical and cognitive 
worsening.72-74 
In summary, a limited number of studies of classic 
MRI abnormalities show CNS pathology, with virtually 
all MRI lesions being associated with CNS injury of 
varying degrees. It is hoped that other easily obtained 
biomarkers will also emerge over time,75 particularly as 
the etiology and pathophysiology of the disease become 
better understood.  
Relationship Between MRI Disease Activity 
and MS Clinical Course: The MRI-Clinical 
Paradox 
Although currently Gd+ and new or enlarging T2 
lesions are the standard conventional MRI features used 
in screening for therapeutic efficacy and are important 
secondary outcome measures in phase 3 trials, their 
relationship to clinical prognosis has been less robust 
than anticipated.76-83 This has led to the concept of a 
mismatch between MRI findings and clinical outcome, 
referred to as the “MRI-clinical paradox.” In fact, some 
researchers have suggested that, given the absence of a 
clear correlation between presence of Gd+ or T2 lesions 
and clinical findings, MRI evidence of inflammation 
may not be of great value as a surrogate for relapses, 
progression in disability, or the need to reconsider choice 
of therapeutic drugs.19,77-83 However, many plausible rea-
sons can be put forward to explain why the MRI-clinical 
paradox may no longer be the enigma it once was, and 
indeed the paradigm is now shifting.31 For example, 
mild clinical relapses may not be documentable if they 
do not meet established EDSS or Functional Systems 
Scale (FSS) criteria, patients do not bring them to medi-
cal attention, or they occur in less eloquent brain areas. 
Subclinical MRI exacerbations are quite common, being 
detected up to 10 times more frequently than clinical 
symptoms or findings in RRMS patients.25-28,49 
Further, as previously indicated, progression can 
be difficult to assess.16-18 The rate of deterioration in 
patients with established disability may be slow, in 
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Meta-analysis of Large Randomized MS Trials 
Until recently, attempts to show that conventional 
MRI is a surrogate for clinical relapses and progres-
sion were limited and not very robust.76-82 This situ-
ation started to change when it was shown that MRI 
reflected not only pathology but also clinical prognosis 
and response to therapy. Subsequently, a meta-analysis 
of all large randomized placebo-controlled studies of 
patients with RRMS was carried out by Sormani et al.106-
109 In the initial study, 23 trials involving 6591 patients 
were analyzed. It was demonstrated that the therapeu-
tic response effect on new MRI T2 lesions correlated 
strongly with the effect of drugs on relapses (adjusted R2 
= 0.81). In a second study, these investigators carried out 
a similar analysis of 11 trials involving 10,009 patients 
with complete data on MRI and disability progression. 
This meta-analysis also showed a significant correlation 
of MRI response to therapy with effect on disability 
progression (adjusted R2 = 0.57) over the 2 to 3 years of 
the study. These and two subsequent studies based on 
individual patient analysis showed that MRI markers 
satisfy the rigorous Prentice criteria for consideration as 
a valid surrogate marker in group studies of RRMS.108-110 
In considering the impact of these studies, it is impor-
tant to remember that while one may not always see a 
robust relationship between MRI and clinical course in 
individual study patients, neither does one always see 
a robust effect of treatment with a drug that has been 
proven clinically effective in a cohort of patients in all 
individual members of the cohort.
At present, sophisticated research MRI studies such as 
fMRI, MTI, DTI, spectroscopy, and the use of stronger 
magnets or other MRI outcomes are not being consid-
ered for incorporation into the current Lublin-Reingold 
clinical classification because they are not generally avail-
able for use in clinical practice and do not show clear 
differences in MRI subclinical relapses, including altera-
tion of BBB and inflammation, between Lublin-Rein-
gold patient categories. For the same reasons, we did not 
take into consideration data on brain atrophy for this 
discussion on clinical classification. 
Discussion
After the presentations further group discussions were 
held (Durelli, Traboulsee), as well as a final discussion to 
review the evidence available and assess the desirability 
of incorporating standard MRI metrics into the current 
Lublin-Reingold criteria for MS disease classification. 
ing number of reports from observational, retrospective, 
randomized, and prospective studies show a much stron-
ger correlation than was found previously between MS 
MRI and clinical disease activity.18,59,90-100 For example, 
RRMS and CIS patients with elevated Gd+ and T2 
lesion activity, in terms of number or volume of lesions 
before or after therapy, have a greater likelihood of sub-
sequent clinical relapses, disability progression, cognitive 
impairment, decreased quality of life, and even death as 
compared with patients with lower or absent MRI activ-
ity.18,59,90-100 Although most of these studies have been 
relatively short term, some have followed study cohorts 
for 20 or more years.100-102
Patterns of MRI Activity and Clinical Course 
In the BECOME study, a sensitive monthly (for up 
to 24 months) MRI technique (3-T scanner, up to a 
40-minute delay in postcontrast imaging, and triple-dose 
Gd administration, all of which increase lesion conspi-
cuity)102-105 was used along with periodic clinical and 
cognitive assessments to study patients with early MS 
and CIS randomized to interferon beta-1b (IFNβ-1b) 
or glatiramer acetate (GA).18,26,37 Scans were obtained 
at baseline before patients were started on IFNβ-1b 
or GA and regularly thereafter. On post hoc analy-
sis, three categories of MRI patterns were apparent.18 
One patient group never had Gd+ or new T2 lesions 
(23.2%); another group had continuous Gd+ or new T2 
lesions with the exception of at most 1 inactive month 
between active MRI months (30.4%); and a third group 
had an intermediate pattern of MRI monthly activity 
(46.4%). Overall, no clinical relationship was found in 
this relatively small number of study patients between 
MRI pattern and drug treatment. However, subset 
analysis showed that patients with active MRI patterns 
had a higher relapse rate, greater sustained worsening in 
the Timed 25-Foot Walk, and more cognitive impair-
ment—the latter both at baseline and subsequently 
during the study—than those without active MRIs. 
This is the first time that such clinical outcomes have 
been so clearly related to MRI patterns; moreover, it is 
remarkable that this could be seen with so few patients, 
all of whom were on therapy. In addition, 75% to 80% 
of patients had MRI activity at some point during the 
BECOME study.26 This reinforces that what we see in 
clinical practice or during clinical trials using infrequent, 
less sensitive MRIs represents just a fraction of what is 
actually occurring in the neuraxis.
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of MS, although it was hoped that this situation would 
change in the future. Moreover, there was a consensus 
that, as with MS diagnostic criteria, the clinical clas-
sification likely would undergo periodic modification, 
particularly as metrics based on currently experimental 
quantitative measures become generally available and 
relevant. o
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